Name: Azetukalner (XEN1101) in Focal onset seizures: Access and distribution
Published: 2026-09-21T21:41:53-04:00

Product information and disease description Product description Product information

Access and distribution

2 evidence topics · 1 source

Absence of an existing commercial and distribution infrastructure

“We do not have a sales or marketing infrastructure and, as a company, have no sales, marketing or distribution experience. Our strategy involves building our own commercial infrastructure to selectively commercialize future products in certain commercial markets which will be expensive and time consuming. For certain products, including azetukalner, and/or specific commercial markets, we evaluate commercial partners from time to time.” (opens the source at this quote in a new tab)

Reliance on contract manufacturers for commercial supply

“We do not own or operate manufacturing or testing facilities for the production of clinical or commercial quantities of our product candidates, and we lack the resources and the capabilities to do so. As a result, we currently rely on third parties for the manufacture and supply of the active pharmaceutical ingredients, or APIs, in our product candidates and the final drug product formulation” (opens the source at this quote in a new tab)